Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07396909 · ClinicalTrials.gov registry record · Phase 1

A First-in-Human Single and Multiple Ascending Dose Study of MT-701

A Phase 1 study of Healthy Volunteers, sponsored by Mirador Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
78
Enrollment target
1
Study location

NCT07396909 is a Phase 1 study of Healthy Volunteers that is actively recruiting participants, run by Mirador Therapeutics. The registered enrollment target is 78 participants, below the 481-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07396909, a Phase 1 study of Healthy Volunteers, is actively recruiting participants, sponsored by Mirador Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
78 participants
Enrollment target
1
Study location

Study Summary

First-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of single and multiple doses of MT-701 in healthy participants.

Conditions Studied

Interventions

  • DRUG MT-701

Study Locations (1)

California

  • Mirador Clinical Department - San Diego

Trial Details

FieldValue
Enrollment Target 78 participants
Start Date 2026-01-12
Est. Completion 2026-10-01
Phase Phase 1

Sponsor

Mirador Therapeutics

5 total trials

What the Registry Record Tells You About NCT07396909

The ClinicalTrials.gov registry entry for NCT07396909 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 481-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (84% lower). The listed sponsor is Mirador Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Volunteers appearing as the primary indexed condition, and to 1 intervention - of which MT-701 is the first listed.

NCT07396909 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT07396909 about?

NCT07396909 is a clinical study titled "A First-in-Human Single and Multiple Ascending Dose Study of MT-701". First-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of single and multiple doses of MT-701 in healthy participants.

What is the current status of trial NCT07396909?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 78 participants. The study started on 2026-01-12. Estimated completion is 2026-10-01.

What conditions does trial NCT07396909 study?

This clinical trial studies the following conditions: Healthy Volunteers.

What interventions are being tested in trial NCT07396909?

The interventions under investigation include: MT-701 (DRUG).

Who is sponsoring clinical trial NCT07396909?

This trial is sponsored by Mirador Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07396909 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteers

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.